CRF receptor antagonists and methods relating thereto

A compound having the following structure:

• including stereoisomers and pharmaceutically acceptable salts thereof, wherein:
• R1 is —CH(R4)(R5);
• R2 is C1-6alkyl;
• R3 is hydrogen or C1-6alkyl;
• R4 is hydrogen, C1-6alkyl, mono- or di(C3-6cycloalkyl)methyl, C3-6cycloalkyl, C3-6alkenyl, hydroxyC1-6alkyl, C1-6alkylcarbonyloxyC1-6alkyl, or C1-6alkyloxyC1-6alkyl, and
• R5 is C1-8alkyl, mono- or di(C3-6cycloalkyl)methyl, Ar1CH2, C3-6alkenyl, C1-6alkyloxyC1-6alkyl, hydroxyC1-6alkyl, thienylmethyl, furanylmethyl, C1-6alkylthioC1-6alkyl, morpholinyl, mono- or di(C1-6alkyl)aminoC1-6alkyl, di(C1-6alkyl)amino, C1-6alkylcarbonylC1-6alkyl, C1-6alkyl substituted with imidazolyl, —CH2Obenzyl, or a radical of the formula —(C1-6alkanediyl))—O—CO—Ar1,
• or R4 and R5 taken together with the carbon atom to which they are bonded form a C5-8cycloalkyl optionally substituted with one or more substituents independently selected from C1-6alkyl;
• Ar is phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C1-6alkyl, trifluoromethyl, cyano, C1-6alkyloxy, benzyloxy, C1-6alkylthio, nitro, amino, and mono- or di(C1-6alkyl)amino;
• or an aromatic C3-12heterocycle optionally substituted with 1, 2 or 3 substituents independently selected from halo, C1-6alkyl, trifluoromethyl, hydroxy, cyano, C1-6alkyloxy, benzyloxy, C1-6alkylthio, nitro, amino, mono- or di(C1-6alkyl)amino, and piperidinyl;
• and
• Ar1is phenyl, pyridinyl, or phenyl substituted with 1, 2 or 3 substituents independently selected from halo, C1-6alkyl, C1-6alkyloxy, di(C1-6alkyl)aminoC1-6alkyl, trifluoromethyl and C1-6alkyl substituted with morpholinyl.